Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 605 articles:
HTML format



Single Articles


    January 2025
  1. SWEET K, Cluzeau T
    Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:61-68.
    PubMed     Abstract available


  2. COSTA A, Scalzulli E, Breccia M
    Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
    Br J Haematol. 2025;206:44-60.
    PubMed     Abstract available


  3. HA TQ, Andresen V, Erikstein BS, Popa M, et al
    Preclinical activity of resazurin in acute myeloid leukaemia.
    Br J Haematol. 2025;206:109-119.
    PubMed     Abstract available


  4. JIANG L, Cheng J, Sun J, Zhang Y, et al
    Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
    Br J Haematol. 2025;206:250-262.
    PubMed     Abstract available


  5. VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al
    Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
    Br J Haematol. 2025;206:204-208.
    PubMed     Abstract available


  6. DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al
    Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.
    Br J Haematol. 2025;206:33-43.
    PubMed     Abstract available


  7. TRKA J, Fronkova E
    Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?
    Br J Haematol. 2025;206:397-398.
    PubMed     Abstract available


  8. HUANG Q, Jiang X, Wang B, Wu Z, et al
    Gallic acid enhances GVL effects of T cells without exacerbating GVHD after haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:120-132.
    PubMed     Abstract available


  9. THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al
    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
    Br J Haematol. 2025;206:186-194.
    PubMed     Abstract available


  10. COUSSON S, Calvo C, Goldwirt L, Simonin M, et al
    Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.
    Br J Haematol. 2025;206:209-214.
    PubMed     Abstract available


    December 2024
  11. FROST EL, Chonat S, Williams KM, Aumann W, et al
    Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
    Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
    PubMed    


  12. HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
    Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
    Br J Haematol. 2024;205:2295-2304.
    PubMed     Abstract available


  13. MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
    Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:2376-2386.
    PubMed     Abstract available


  14. KONDO T
    A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:2131-2133.
    PubMed     Abstract available


  15. PULA AE, Robak T
    The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
    Br J Haematol. 2024;205:2125-2127.
    PubMed     Abstract available


  16. BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
    Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
    Br J Haematol. 2024;205:2153-2162.
    PubMed     Abstract available


  17. JAYNE S, Lopez C, Put N, Nagel I, et al
    The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
    Br J Haematol. 2024;205:2321-2326.
    PubMed     Abstract available


  18. TERUEL-MONTOYA R, Rivera J, Lozano ML
    The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
    Br J Haematol. 2024;205:2122-2124.
    PubMed     Abstract available


  19. KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
    Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
    Br J Haematol. 2024;205:2315-2320.
    PubMed     Abstract available


  20. LIU W, Wang C, Ouyang W, Hao J, et al
    Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
    Br J Haematol. 2024;205:2228-2233.
    PubMed     Abstract available


  21. ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
    Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
    Br J Haematol. 2024;205:2234-2247.
    PubMed     Abstract available


    November 2024
  22. LV M, Yan CH, Ma R, He Y, et al
    Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
    Br J Haematol. 2024;205:1910-1920.
    PubMed     Abstract available


  23. BOULIGNY IM, DiNardo CD
    Oral decitabine-cedazuridine in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1674-1676.
    PubMed     Abstract available


  24. GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
    Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
    Br J Haematol. 2024;205:1734-1745.
    PubMed     Abstract available


  25. PHILIP C, Selvarajan S, Nayak L, Jain H, et al
    Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
    Br J Haematol. 2024;205:2058-2062.
    PubMed     Abstract available


  26. YANADA M
    Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
    Br J Haematol. 2024;205:1672-1673.
    PubMed     Abstract available


  27. MAILLET F, Galimard JE, Borie R, Lainey E, et al
    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
    Br J Haematol. 2024;205:1835-1847.
    PubMed     Abstract available


  28. ARIFFIN H
    Incorrigible inflammation.
    Br J Haematol. 2024;205:1679-1680.
    PubMed     Abstract available


  29. CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
    Br J Haematol. 2024;205:1727-1733.
    PubMed     Abstract available


  30. SPECTOR LG, de Smith AJ
    Backtracking childhood leukaemia to birth: A battle of addition.
    Br J Haematol. 2024;205:1670-1671.
    PubMed     Abstract available


  31. YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
    Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
    Br J Haematol. 2024;205:1751-1764.
    PubMed     Abstract available


  32. XU N, Dao FT, Shi ZY, Sun K, et al
    WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1848-1859.
    PubMed     Abstract available


  33. ZHU Q, Nambiar R, Schultz E, Gao X, et al
    Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1889-1898.
    PubMed     Abstract available


  34. BARDINI M, Fazio G, Abascal LC, Meyer C, et al
    Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1883-1888.
    PubMed     Abstract available


  35. WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
    Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
    Br J Haematol. 2024;205:1746-1750.
    PubMed     Abstract available


    October 2024
  36. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    PubMed     Abstract available


  37. NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al
    Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Br J Haematol. 2024;205:1430-1443.
    PubMed     Abstract available


  38. GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al
    Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:1395-1403.
    PubMed     Abstract available


  39. GAO MY, Georgiou A, Lin VS, Jahja M, et al
    Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.
    Br J Haematol. 2024;205:1389-1394.
    PubMed     Abstract available


  40. MEHTA P, Campbell V, Maddox J, Floisand Y, et al
    CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Br J Haematol. 2024;205:1326-1336.
    PubMed     Abstract available


  41. ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al
    Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
    Br J Haematol. 2024;205:1450-1459.
    PubMed     Abstract available


    September 2024
  42. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    PubMed     Abstract available


  43. HEI Z, Yang S, Ouyang G, Hanna J, et al
    Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.
    Br J Haematol. 2024;205:1017-1030.
    PubMed     Abstract available


  44. LEBLANC FR, Breese EH, Burns KC, Chang EK, et al
    Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
    Br J Haematol. 2024;205:1055-1066.
    PubMed     Abstract available


  45. HUANG C, Jia Y, Yang J, Cai Y, et al
    Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
    Br J Haematol. 2024;205:1067-1076.
    PubMed     Abstract available


  46. GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al
    Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
    Br J Haematol. 2024;205:1011-1016.
    PubMed     Abstract available


  47. KUGLER E, Cohen I, Amitai I, Ram R, et al
    Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;205:932-941.
    PubMed     Abstract available


  48. KUHN MWM, Ganser A
    The Menin story in acute myeloid leukaemia-The road to success.
    Br J Haematol. 2024;205:812-814.
    PubMed     Abstract available


  49. ZHAO S, Wang J, Lou Y, Huang X, et al
    Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study.
    Br J Haematol. 2024;205:924-931.
    PubMed     Abstract available


  50. ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al
    Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.
    Br J Haematol. 2024;205:947-955.
    PubMed     Abstract available


  51. MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al
    Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
    Br J Haematol. 2024;205:915-923.
    PubMed     Abstract available


    August 2024
  52. GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al
    Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute myeloid leukaemia with NPM1 mutation.
    Br J Haematol. 2024;205:401-402.
    PubMed    


  53. YANG F, Ren Q, Zu Y, Gui R, et al
    Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:645-652.
    PubMed     Abstract available


  54. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
    MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell acute lymphoblastic leukaemia: A national cohort analysis.
    Br J Haematol. 2024;205:729-732.
    PubMed    


  55. CHEN C, Li J, Chen Y, Gao Q, et al
    The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:624-633.
    PubMed     Abstract available


  56. ZHU W, Ding Y, Huang W, Guo N, et al
    Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
    Br J Haematol. 2024;205:568-579.
    PubMed     Abstract available


  57. GRADY E, Biswas S, Dias T, McCarthy P, et al
    A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:738-741.
    PubMed    


  58. OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al
    Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:711-715.
    PubMed    


  59. WANG S, Liu Y, Zhao X, Wang X, et al
    RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
    Br J Haematol. 2024;205:552-567.
    PubMed     Abstract available


  60. TANG FF, Duan WB, Liu XH, Lu SY, et al
    A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
    Br J Haematol. 2024;205:510-516.
    PubMed     Abstract available


  61. NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al
    Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Br J Haematol. 2024;205:495-502.
    PubMed     Abstract available


  62. XU X, Huang Z, Ding C, Deng S, et al
    STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:517-528.
    PubMed     Abstract available


  63. BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al
    T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
    Br J Haematol. 2024;205:607-612.
    PubMed     Abstract available


    July 2024
  64. ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al
    Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
    Br J Haematol. 2024;205:207-219.
    PubMed     Abstract available


  65. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
    Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
    Br J Haematol. 2024;205:280-290.
    PubMed     Abstract available


  66. JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al
    Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
    Br J Haematol. 2024;205:256-267.
    PubMed     Abstract available


  67. PICHLER H, Sedlacek P, Meisel R, Beier R, et al
    Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
    Br J Haematol. 2024;205:268-279.
    PubMed     Abstract available


  68. TAURINO G, Dander E, Chiu M, Pozzi G, et al
    Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
    Br J Haematol. 2024;205:175-188.
    PubMed     Abstract available


  69. WANG HY, Louis HMS, Costello CL, Murray SS, et al
    A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
    Br J Haematol. 2024;205:364-367.
    PubMed    


  70. DOURTHE ME, Yakouben K, David A, Thouvenin S, et al
    Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:373-377.
    PubMed    


  71. JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al
    Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
    Br J Haematol. 2024;205:30-47.
    PubMed     Abstract available


  72. SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al
    Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
    Br J Haematol. 2024;205:189-193.
    PubMed     Abstract available


  73. ZHANG X, Zhong Y, Liu L, Suo S, et al
    MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
    Br J Haematol. 2024;205:352-355.
    PubMed    


  74. IYENGAR L, Fong CY, Prakash S, Chong AH, et al
    Cutaneous involvement in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:11.
    PubMed    


  75. POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al
    Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
    Br J Haematol. 2024;205:158-165.
    PubMed     Abstract available


    June 2024
  76. XU J, Peng J, Sun S, Wang D, et al
    Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2301-2318.
    PubMed     Abstract available


  77. DELGADO J
    InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Br J Haematol. 2024;204:2155-2156.
    PubMed     Abstract available


  78. ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al
    Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
    Br J Haematol. 2024;204:2264-2274.
    PubMed     Abstract available


  79. ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al
    A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
    Br J Haematol. 2024;204:2287-2300.
    PubMed     Abstract available


  80. LIU H, Wu K, Hu W, Chen X, et al
    Immunophenotypic clustering in paediatric acute myeloid leukaemia.
    Br J Haematol. 2024;204:2275-2286.
    PubMed     Abstract available


  81. MAO S, Lin Y, Qin X, Miao Y, et al
    Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
    Br J Haematol. 2024;204:2332-2341.
    PubMed     Abstract available


  82. JEN WY, Sasaki K, Loghavi S, Wang SA, et al
    Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
    Br J Haematol. 2024;204:2259-2263.
    PubMed     Abstract available


  83. KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al
    Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;204:2173-2183.
    PubMed     Abstract available


  84. ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al
    Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Br J Haematol. 2024;204:2254-2258.
    PubMed     Abstract available


  85. ONIDA F, Gras L, Ge J, Koster L, et al
    Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
    Br J Haematol. 2024;204:2365-2377.
    PubMed     Abstract available


  86. HARROP S, Nguyen PC, Robinson S, Nguyen T, et al
    Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
    Br J Haematol. 2024;204:2492-2495.
    PubMed    


  87. BARNBROCK A, Moricke A, Barbaric D, Jones N, et al
    Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
    Br J Haematol. 2024;204:2319-2323.
    PubMed     Abstract available


  88. DONG Q, Wang Y, Xiu Y, Wu X, et al
    Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
    Br J Haematol. 2024;204:2487-2491.
    PubMed    


  89. BAUCH T, Hempel G
    Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2324-2331.
    PubMed     Abstract available


    May 2024
  90. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
    Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
    PubMed     Abstract available


  91. BALDUZZI A
    The CAR T-cell race: The rules of the game.
    Br J Haematol. 2024;204:1579-1581.
    PubMed     Abstract available


  92. ZHANG X, Tao C, Long F
    Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
    Br J Haematol. 2024;204:1569-1570.
    PubMed    


  93. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
    Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1687-1696.
    PubMed     Abstract available


  94. KRIEGER E, Qayyum R, Toor A
    Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Br J Haematol. 2024;204:1935-1943.
    PubMed     Abstract available


  95. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
    Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Br J Haematol. 2024;204:1872-1881.
    PubMed     Abstract available


  96. JO T, Ueda T, Akahoshi Y, Kondo T, et al
    First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1913-1919.
    PubMed     Abstract available


  97. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
    HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
    Br J Haematol. 2024;204:1920-1934.
    PubMed     Abstract available


  98. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    PubMed     Abstract available


  99. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
    Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
    Br J Haematol. 2024;204:1732-1739.
    PubMed     Abstract available


    April 2024
  100. HUO W, Gao L, Song K, Huang J, et al
    Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
    PubMed     Abstract available


  101. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
    A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
    Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
    PubMed     Abstract available


  102. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    PubMed     Abstract available


  103. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    PubMed     Abstract available


  104. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    PubMed     Abstract available


  105. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    PubMed     Abstract available


  106. STENTOFT J
    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    PubMed     Abstract available


  107. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    PubMed     Abstract available


  108. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    PubMed     Abstract available


  109. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.
    PubMed    


  110. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    PubMed     Abstract available


  111. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    PubMed     Abstract available


  112. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    PubMed     Abstract available


  113. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    PubMed     Abstract available


  114. FIEDLER W
    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    PubMed     Abstract available


  115. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    PubMed     Abstract available


  116. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    PubMed     Abstract available


  117. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    PubMed     Abstract available


  118. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    PubMed     Abstract available


    March 2024
  119. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    PubMed     Abstract available


  120. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    PubMed     Abstract available


  121. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    PubMed    


  122. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    PubMed     Abstract available


  123. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    PubMed    


  124. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    PubMed     Abstract available


  125. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    PubMed     Abstract available


  126. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    PubMed     Abstract available


  127. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    PubMed     Abstract available


  128. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    PubMed    


  129. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    PubMed     Abstract available


  130. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    PubMed     Abstract available


  131. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    PubMed     Abstract available


    February 2024
  132. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    PubMed     Abstract available


  133. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    PubMed     Abstract available


  134. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.
    PubMed    


  135. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    PubMed     Abstract available


  136. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    PubMed     Abstract available


  137. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.
    PubMed    


  138. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.
    PubMed    


  139. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    PubMed     Abstract available


  140. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    PubMed     Abstract available


  141. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    PubMed     Abstract available


  142. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    PubMed     Abstract available


    January 2024
  143. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
    Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
    PubMed    


  144. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
    Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
    Br J Haematol. 2024;204:240-249.
    PubMed     Abstract available


  145. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
    Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Br J Haematol. 2024;204:16-18.
    PubMed     Abstract available


  146. GJERTSEN BT
    How to discover the exceptional venetoclax responders in AML/MDS?
    Br J Haematol. 2024;204:14-15.
    PubMed    


  147. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
    IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:229-239.
    PubMed     Abstract available


  148. BARON F, Nagler A, Galimard JE, Sanz J, et al
    Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Br J Haematol. 2024;204:250-259.
    PubMed     Abstract available


  149. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
    Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    Br J Haematol. 2024;204:206-220.
    PubMed     Abstract available


  150. NANAA A, He R, Foran JM, Badar T, et al
    Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Br J Haematol. 2024;204:171-176.
    PubMed     Abstract available


  151. MURPHY EL
    HTLV-1 and blood donation.
    Br J Haematol. 2024;204:29-30.
    PubMed     Abstract available


    December 2023
  152. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
    AML in the elderly-A global view.
    Br J Haematol. 2023;203:760-773.
    PubMed    


  153. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    PubMed    


  154. HERRITY E, Pereira MP, Kim DDH
    Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
    Br J Haematol. 2023;203:722-735.
    PubMed     Abstract available


  155. MAHDI D, O'Nions J, Raj K, Baker R, et al
    Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
    Br J Haematol. 2023;203:e114-e116.
    PubMed    


  156. QI P, Wang L, Li H, Wu Y, et al
    Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
    Br J Haematol. 2023;203:892-895.
    PubMed    


  157. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
    Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Br J Haematol. 2023;203:781-791.
    PubMed     Abstract available


  158. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
    Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
    Br J Haematol. 2023;203:699-700.
    PubMed    


    November 2023
  159. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    PubMed     Abstract available


  160. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    PubMed     Abstract available


  161. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    PubMed     Abstract available


  162. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    PubMed     Abstract available


  163. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.
    PubMed    


  164. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    PubMed     Abstract available


  165. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    PubMed     Abstract available


  166. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.
    PubMed    


    October 2023
  167. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    PubMed     Abstract available


  168. PAN X, Chang Y, Ruan G, Wei F, et al
    Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
    Br J Haematol. 2023;203:212-223.
    PubMed     Abstract available


  169. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
    Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Br J Haematol. 2023;203:169-181.
    PubMed     Abstract available


  170. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
    Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Br J Haematol. 2023;203:224-236.
    PubMed     Abstract available


  171. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
    Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
    Br J Haematol. 2023;203:327-330.
    PubMed    


  172. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    PubMed     Abstract available


    September 2023
  173. RHODES J
    FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?
    Br J Haematol. 2023;202:922-924.
    PubMed     Abstract available


  174. RADICH JP
    The (near) miracle of therapy in chronic myeloid leukaemia.
    Br J Haematol. 2023;202:919-921.
    PubMed    


  175. PATNANA PK, Liu L, Frank D, Nimmagadda SC, et al
    Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
    Br J Haematol. 2023;202:1033-1048.
    PubMed     Abstract available


  176. HUA L, Yang N, Li Y, Huang K, et al
    Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
    Br J Haematol. 2023;202:971-984.
    PubMed     Abstract available


  177. LI H, Yuan L, Wang P, Sheng Y, et al
    Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
    Br J Haematol. 2023;202:1055-1060.
    PubMed    


  178. RIGOLIN GM, Traversa A, Caputo V, Del Giudice I, et al
    Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
    Br J Haematol. 2023;202:953-959.
    PubMed     Abstract available


  179. DE JOHN KO, De Quintal H, Mathibe MD, Albertus N, et al
    A rare case of acute megakaryoblastic leukaemia with constitutional ring chromosome 21.
    Br J Haematol. 2023;202:912.
    PubMed    


  180. SHAH NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson SM, et al
    Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
    Br J Haematol. 2023;202:942-952.
    PubMed     Abstract available


  181. BRECCIA M, Saglio G
    Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Br J Haematol. 2023;202:1087-1088.
    PubMed     Abstract available


  182. HADDAD FG, Kourie HR, Saleh K
    Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:1084-1086.
    PubMed     Abstract available


  183. IRANI YD, Hughes A, Kok CH, Clarson J, et al
    Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Br J Haematol. 2023;202:1127-1136.
    PubMed     Abstract available


  184. FENG H, Fu Y, Cui Z, Zhou M, et al
    Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Br J Haematol. 2023;202:1178-1191.
    PubMed     Abstract available


  185. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
    FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Br J Haematol. 2023;202:1137-1150.
    PubMed     Abstract available


  186. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
    Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
    Br J Haematol. 2023;202:1165-1177.
    PubMed     Abstract available


  187. XIE M, Lu Y, Ouyang G, Li X, et al
    Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
    Br J Haematol. 2023;202:1119-1126.
    PubMed     Abstract available


  188. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
    Hairy cell leukaemia with an IGH-BRAF fusion gene.
    Br J Haematol. 2023;202:e67-e70.
    PubMed    


  189. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
    Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
    Br J Haematol. 2023;202:e50-e53.
    PubMed    


    August 2023
  190. LAHERA A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al
    Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.
    Br J Haematol. 2023;202:693-698.
    PubMed    


  191. GE SS, Qiu QC, Dai HP, Shen XD, et al
    Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
    Br J Haematol. 2023;202:539-549.
    PubMed     Abstract available


  192. MA Z, Ye W, Wang J, Huang X, et al
    Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.
    Br J Haematol. 2023;202:566-577.
    PubMed     Abstract available


  193. ZHOU L, Fu W, Wu S, Xu K, et al
    Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Br J Haematol. 2023;202:517-524.
    PubMed     Abstract available


  194. NI SC, Lin CC
    Pseudothrombocytosis in Acute Myeloid Leukaemia.
    Br J Haematol. 2023;202:456.
    PubMed    


  195. MILADINOVIC M, Klusmann JH
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:713-714.
    PubMed     Abstract available


  196. HUO WX, Wen Q, Zhang XH, Xu LP, et al
    Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia.
    Br J Haematol. 2023;202:856-865.
    PubMed     Abstract available


  197. NG LIET HING M, Ryland GL, Nguyen T, Tiong IS, et al
    Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    Br J Haematol. 2023;202:893-896.
    PubMed    


  198. YOU L, Liu Y, Chen N, Zhu L, et al
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:745-748.
    PubMed     Abstract available


  199. RIVA G, Luppi M, Tagliafico E
    From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
    Br J Haematol. 2023;202:715-717.
    PubMed     Abstract available


  200. NGUYEN PC, Nguyen V, Baldwin K, Kankanige Y, et al
    Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2023;202:760-770.
    PubMed     Abstract available


  201. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
    Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
    Br J Haematol. 2023;202:578-588.
    PubMed     Abstract available


  202. LOKE J, Upasani V, Gaskell C, Fox S, et al
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    Br J Haematol. 2023;202:498-503.
    PubMed     Abstract available


  203. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
    A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Br J Haematol. 2023;202:599-607.
    PubMed     Abstract available


  204. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
    Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
    Br J Haematol. 2023;202:589-598.
    PubMed     Abstract available


    July 2023
  205. KASSEM AM, Keinath MC, Adler JA, Gadde R, et al
    ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings.
    Br J Haematol. 2023 Jul 26. doi: 10.1111/bjh.18950.
    PubMed    


  206. FALINI B, Cardinali V, Brunetti L, Martelli MP, et al
    NPM1-mutated AML with starry sky pattern.
    Br J Haematol. 2023;202:8.
    PubMed    


  207. HUO L, Zhang Z, Zhou H, Xie J, et al
    Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:199-203.
    PubMed    


  208. DOAN A, Huang HKT, Hadar AJ, Malvar J, et al
    Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
    Br J Haematol. 2023;202:e3-e6.
    PubMed    


  209. ZHU X, Jiang Q, Lu J, Sun Y, et al
    COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
    Br J Haematol. 2023;202:31-39.
    PubMed     Abstract available


  210. ZHANG X, Wang Z, Sun J, Liu L, et al
    New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;202:111-115.
    PubMed     Abstract available


  211. ERKELAND SJ
    Computational analysis of a microRNA signature for poor prognosis suggests a microRNA-controlled stemness pathway in paediatric acute leukaemia.
    Br J Haematol. 2023;202:11-12.
    PubMed     Abstract available


  212. FIGUEROA-MORA R, Rampotas A, Halperin D, Worth T, et al
    Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
    Br J Haematol. 2023;202:48-53.
    PubMed     Abstract available


  213. ESPERANZA-CEBOLLADA E, Gomez-Gonzalez S, Perez-Jaume S, Vega-Garcia N, et al
    A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;202:96-110.
    PubMed     Abstract available


  214. JO T, Arai Y, Oshima S, Kondo T, et al
    Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
    Br J Haematol. 2023;202:356-368.
    PubMed     Abstract available


  215. SYSTCHENKO T, Chomel JC, Gallego-Hernanz P, Moya N, et al
    Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Br J Haematol. 2023;202:284-288.
    PubMed     Abstract available


  216. STRULLU M, Fenneteau O, Lainey E
    Cannibalism in an ETV6::RUNX1 paediatric B acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:211.
    PubMed    


  217. LI T, Zhang Y, Wang K, Zhou H, et al
    Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation.
    Br J Haematol. 2023;202:212.
    PubMed    


  218. LV M, Liu L, He Y, Yang D, et al
    Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
    Br J Haematol. 2023;202:369-378.
    PubMed     Abstract available


  219. OFVERHOLM I, Rezayee F, Heyman M, Harila A, et al
    The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
    Br J Haematol. 2023;202:384-392.
    PubMed     Abstract available


  220. WANG W, Li X, Qin X, Miao Y, et al
    Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
    Br J Haematol. 2023;202:328-343.
    PubMed     Abstract available


  221. GURNEY M, Chekkaf I, Baranwal A, Basmaci R, et al
    The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
    Br J Haematol. 2023;202:279-283.
    PubMed     Abstract available


    June 2023
  222. MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
    Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
    PubMed     Abstract available


  223. TURNER R, Quach H, Horvath N, Kerridge I, et al
    Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
    Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
    PubMed     Abstract available


  224. LIU Y, Zhu L, Lv Z, Mao L, et al
    Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Br J Haematol. 2023;201:995-999.
    PubMed    


  225. XIE X, Zhang W, Zhou X, Ye Z, et al
    Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Br J Haematol. 2023;201:940-953.
    PubMed     Abstract available


  226. VAINER N, Aarup K, Andersen MA, Wind-Hansen L, et al
    Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:874-886.
    PubMed     Abstract available


  227. RIEU JB, Canali A, Thene E, Tavitian S, et al
    Acute promyelocytic leukaemia associated with atypical basophilia.
    Br J Haematol. 2023;201:1017.
    PubMed    


  228. YOKOYAMA S, Onozawa M, Yoshida S, Miyashita N, et al
    Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
    Br J Haematol. 2023;201:1144-1152.
    PubMed     Abstract available


  229. SIMOES C, Villar S, Ariceta B, Garces JJ, et al
    Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
    Br J Haematol. 2023;201:1239-1244.
    PubMed    


  230. BRONSTEIN Y, Levi S, Herishanu Y
    Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
    Br J Haematol. 2023;201:1125-1128.
    PubMed     Abstract available


  231. DULUCQ S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, et al
    Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
    Br J Haematol. 2023;201:1116-1124.
    PubMed     Abstract available


  232. MENEZES DL, See WL, Risueno A, Tsai KT, et al
    Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
    Br J Haematol. 2023;201:1129-1143.
    PubMed     Abstract available


  233. NAGLER A, Labopin M, Dholaria B, Blaise D, et al
    Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
    Br J Haematol. 2023;201:1169-1178.
    PubMed     Abstract available


  234. ISHIDA H, Imamura T, Tatebe Y, Ishihara T, et al
    Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
    Br J Haematol. 2023;201:1200-1208.
    PubMed     Abstract available


    May 2023
  235. PUCKRIN R, Owen C, Stewart D, Peters A, et al
    Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
    Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.
    PubMed    


  236. SAVOY L, Long N, Lee H, Chen R, et al
    CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
    Br J Haematol. 2023 May 14. doi: 10.1111/bjh.18843.
    PubMed    


  237. JEDIDI I, Krichen I, Chaari M, Louati N, et al
    Auer-rod like inclusions in mature neutrophils of an early T cell precursor lymphoblastic leukaemia patient after SARS-CoV-2 infection.
    Br J Haematol. 2023;201:378.
    PubMed    


  238. LUNDIN-STROM KB, Biloglav A, Castor A, Olsson-Arvidsson L, et al
    Acquired uniparental isodisomies involving chromosome 12 in paediatric B-cell precursor acute lymphoblastic leukaemia: Associations with chromosome 21 gains and SH2B3 mutations.
    Br J Haematol. 2023;201:585-588.
    PubMed    


  239. WANG H, Yao Y, Mao L, Lou Y, et al
    Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
    Br J Haematol. 2023;201:568-572.
    PubMed    


  240. MAURO FR, Visentin A, Giannarelli D, Molinari MC, et al
    Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
    Br J Haematol. 2023;201:564-567.
    PubMed    


  241. JING CB, Prutsch N, He S, Zimmerman MW, et al
    Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
    Br J Haematol. 2023;201:489-501.
    PubMed     Abstract available


  242. CARRILLO-TORNEL S, Chen-Liang TH, Zurdo M, Puiggros A, et al
    NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.
    Br J Haematol. 2023;201:470-479.
    PubMed     Abstract available


  243. TIACCI E, Mancini A, Marchetti M, D'Elia GM, et al
    SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
    Br J Haematol. 2023;201:411-416.
    PubMed     Abstract available


  244. JONART LM, Ostergaard J, Brooks A, Fitzpatrick G, et al
    CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
    Br J Haematol. 2023;201:459-469.
    PubMed     Abstract available


  245. POPOV A, Tsaur G, Verzhbitskaya T, Riger T, et al
    Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Br J Haematol. 2023;201:510-519.
    PubMed     Abstract available


  246. COLLIGNON C, Domenech C, Ducassou S, Pluchart C, et al
    Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:e42-e45.
    PubMed    


  247. CHEN R, Atenafu EG, Seki J, Liu X, et al
    Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:645-652.
    PubMed     Abstract available


  248. LAHERA A, Lopez-Nieva P, Alarcon H, Marin-Rubio JL, et al
    SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
    Br J Haematol. 2023;201:718-724.
    PubMed     Abstract available


  249. HAMA A, Taga T, Tomizawa D, Muramatsu H, et al
    Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
    Br J Haematol. 2023;201:747-756.
    PubMed     Abstract available


  250. KARLSSON L, Cheuk D, De Moerloose B, Hasle H, et al
    Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;201:757-765.
    PubMed     Abstract available


    April 2023
  251. CASTAGNA L, Patti K, Mule A
    Don't forget cord blood in non-remission acute myeloid leukaemia!
    Br J Haematol. 2023;201:11-12.
    PubMed     Abstract available


  252. ZHENG Y, Weng X, Hu D, He J, et al
    Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia.
    Br J Haematol. 2023;201:95-105.
    PubMed     Abstract available


  253. SORCINI D, De Falco F, Gargaro M, Bozza S, et al
    Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:45-57.
    PubMed     Abstract available


  254. MATSUDA K, Konuma T, Fuse K, Masuko M, et al
    Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study.
    Br J Haematol. 2023;201:106-113.
    PubMed     Abstract available


  255. DEL GIUDICE I, Cappelli LV, Delgado J, Niemann CU, et al
    Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
    Br J Haematol. 2023;201:353-356.
    PubMed    


  256. WANG YH, Yao CY, Lin CC, Gurashi K, et al
    A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;201:302-307.
    PubMed     Abstract available


  257. MA H, Wang S, O'Brien S, Kern M, et al
    How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.
    Br J Haematol. 2023;201:215-221.
    PubMed     Abstract available


  258. SALOMAO N, Maslah N, Giulianelli A, Drevon L, et al
    Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
    Br J Haematol. 2023;201:234-248.
    PubMed     Abstract available


  259. SINGH C, Yanamandra U, Karunakaran P, Jindal N, et al
    Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
    Br J Haematol. 2023;201:249-255.
    PubMed     Abstract available


    March 2023
  260. SPACEK M, Smolej L, Simkovic M, Nekvindova L, et al
    Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18736.
    PubMed     Abstract available


  261. SHEN K, Yang C
    Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.
    PubMed    


  262. ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
    Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.
    PubMed    


  263. EL HUSSEIN S, Wang W
    Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations.
    Br J Haematol. 2023;200:545-555.
    PubMed     Abstract available


  264. FRISCH A, Rowe JM, Ofran Y
    The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
    Br J Haematol. 2023;200:556-562.
    PubMed     Abstract available


  265. MATSUDA K, Konuma T, Yanada M
    Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors' reply.
    Br J Haematol. 2023;200:678-679.
    PubMed    


  266. SCARADAVOU A, Boelens JJ
    Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML.
    Br J Haematol. 2023;200:676-677.
    PubMed    


  267. MUSSAI F, De Santo C, Cheng P, Thomas IF, et al
    A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2023;200:573-578.
    PubMed     Abstract available


  268. CHOI Y, Choi EJ, Park HS, Lee JH, et al
    A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
    Br J Haematol. 2023;200:608-621.
    PubMed     Abstract available


  269. AGUILAR NAVARRO AG, Tikhonova AN
    Treatment response in acute myeloid leukaemia-Clues in the biopsy core.
    Br J Haematol. 2023;200:691-693.
    PubMed     Abstract available


  270. TREABA DO, Bonal DM, Chorzalska A, Castillo-Martin M, et al
    Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
    Br J Haematol. 2023;200:740-754.
    PubMed     Abstract available


    February 2023
  271. MESZAROS N, Lind K, Sehlke R, Vilagos B, et al
    Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues.
    Br J Haematol. 2023;200:e32-e36.
    PubMed    


  272. MANGUM DS, Bishop JD, Zhou Y, Cheng C, et al
    Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis.
    Br J Haematol. 2023;200:338-343.
    PubMed     Abstract available


  273. CHATTERJEE G, Patkar N
    United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Br J Haematol. 2023;200:277-279.
    PubMed     Abstract available


  274. BARNES EJ, Eide CA, Kaempf A, Bottomly D, et al
    Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
    Br J Haematol. 2023;200:323-328.
    PubMed     Abstract available


  275. IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
    Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Br J Haematol. 2023;200:381-384.
    PubMed    


  276. KULIS M, Martin-Subero JI
    Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications.
    Br J Haematol. 2023;200:280-290.
    PubMed     Abstract available


  277. GOURSAUD L, Berthon C, Quesnel B
    Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
    Br J Haematol. 2023;200:e37-e39.
    PubMed    


  278. RAKOTOARIVELO ZH, Lefebvre T, Lamarque M, Harzallah I, et al
    Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11.
    Br J Haematol. 2023;200:398.
    PubMed    


  279. TIAN C, Chen Z, Wang L, Si J, et al
    Over expression of ubiquitin-conjugating enzyme E2O in bone marrow mesenchymal stromal cells partially attenuates acute myeloid leukaemia progression.
    Br J Haematol. 2023;200:476-488.
    PubMed     Abstract available


  280. HUANG T, Xu L, Zhang X, Chang Y, et al
    Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;200:494-505.
    PubMed     Abstract available


  281. MADRY K, Lis K, Fenaux P, Bowen D, et al
    Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
    Br J Haematol. 2023;200:451-461.
    PubMed     Abstract available


  282. DARGENIO M, Bonifacio M, Chiaretti S, Vitale A, et al
    Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
    Br J Haematol. 2023;200:440-450.
    PubMed     Abstract available


  283. GJAERDE LK, Jakobsen LH, Juhl-Christensen C, Olesen G, et al
    Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
    Br J Haematol. 2023;200:e40-e43.
    PubMed    


    January 2023
  284. WILSON J
    Pseudo-faggot cells in splenic marginal zone lymphoma.
    Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.
    PubMed    


  285. OLOFSEN PA, Bosch DA, de Looper HWJ, van Strien PMH, et al
    Truncated CSF3 receptors induce pro-inflammatory responses in severe congenital neutropenia.
    Br J Haematol. 2023;200:79-86.
    PubMed     Abstract available


  286. ZHANG T, Liu X, Fei H, Zhang L, et al
    Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;200:256-260.
    PubMed    


  287. PAUL SR, Rosing DR, Haigney MC, Peer CJ, et al
    Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;200:261-263.
    PubMed    


  288. WIERNIK PH
    Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
    Br J Haematol. 2023;200:126-127.
    PubMed     Abstract available


  289. GURNARI C, Pagliuca S
    Digging into the HLA pockets: A new association with acute leukaemias.
    Br J Haematol. 2023;200:123-125.
    PubMed     Abstract available


  290. MEHTA P, Telford N, Wragg C, Dillon R, et al
    Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
    Br J Haematol. 2023;200:150-159.
    PubMed    


  291. BOUKOUACI W, Rivera-Franco MM, Volt F, Wu CL, et al
    Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia.
    Br J Haematol. 2023;200:197-209.
    PubMed     Abstract available


  292. PEREIRA-MARTINS DA, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, et al
    Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
    Br J Haematol. 2023;200:170-174.
    PubMed     Abstract available


  293. ROY L, Chomel JC, Guilhot J, Guerci-Bresler A, et al
    Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Br J Haematol. 2023;200:175-186.
    PubMed     Abstract available


    December 2022
  294. LI H, Xiang X, Ding H, Yu J, et al
    Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Br J Haematol. 2022;199:768-771.
    PubMed    


  295. CANALI A, Rieu JB
    Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
    Br J Haematol. 2022;199:638.
    PubMed    


  296. WEI S, Gu R, Song Y, Yan Z, et al
    Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
    Br J Haematol. 2022;199:772-776.
    PubMed    


  297. ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
    Acute myeloid leukaemia presenting with Sweet syndrome.
    Br J Haematol. 2022;199:637.
    PubMed    


  298. MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
    Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Br J Haematol. 2022;199:707-719.
    PubMed     Abstract available


  299. COPLAND M
    Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
    Br J Haematol. 2022;199:665-678.
    PubMed     Abstract available


    November 2022
  300. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
    PubMed    


  301. RIO-MACHIN A
    ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours.
    Br J Haematol. 2022;199:307-309.
    PubMed    


  302. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    PubMed     Abstract available


  303. LI T, Wu P, Wang A, Chen M, et al
    A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia.
    Br J Haematol. 2022;199:305.
    PubMed    


  304. FORDHAM NJ, Bartram J, Ghorashian S, O'Connor D, et al
    What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
    Br J Haematol. 2022;199:447-451.
    PubMed    


  305. SHANMUGANATHAN N, Hughes TP
    Asciminib for chronic myeloid leukaemia: Next questions.
    Br J Haematol. 2022;199:322-331.
    PubMed     Abstract available


  306. WAN Y, Zhang H, Zhang L, Cai J, et al
    Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:587-596.
    PubMed     Abstract available


  307. WANG Y, Chen S, Chi P, Nie R, et al
    Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Br J Haematol. 2022;199:572-586.
    PubMed     Abstract available


  308. KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
    Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
    Br J Haematol. 2022;199:539-548.
    PubMed     Abstract available


  309. ZHAO C, Wang S, Wang K
    Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
    Br J Haematol. 2022;199:e25-e29.
    PubMed    


  310. QIANG X, Chen S, Chen X
    Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
    Br J Haematol. 2022;199:475.
    PubMed    


  311. KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
    GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Br J Haematol. 2022;199:482-495.
    PubMed     Abstract available


    October 2022
  312. ANDERSSON NG, Rathe M, Molle I, Jarvis KB, et al
    A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
    Br J Haematol. 2022;199:117-121.
    PubMed     Abstract available


  313. BARRETT J
    Screening for mercaptopurine intolerance in ALL - target the genes or their product?
    Br J Haematol. 2022;199:173-174.
    PubMed     Abstract available


  314. DENNIS M, Copland M, Kaur H, Kell J, et al
    Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
    Br J Haematol. 2022;199:205-221.
    PubMed    


  315. TANAKA Y, Urayama KY, Mori M, Arakawa Y, et al
    Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:260-269.
    PubMed     Abstract available


  316. YOSHIDA M, Brown SA, Moriyama T, Nishii R, et al
    Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
    Br J Haematol. 2022;199:270-276.
    PubMed     Abstract available


  317. DILLON J, Mykytiv V, Keenan C, Mullaney B, et al
    Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene.
    Br J Haematol. 2022;199:e5-e7.
    PubMed    


  318. ALSOUQI A, Rothenberger SD, Boyiadzis M, Lontos K, et al
    Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
    Br J Haematol. 2022;199:256-259.
    PubMed     Abstract available


  319. HAMPEL PJ, Rabe KG, Call TG, Ding W, et al
    Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;199:239-244.
    PubMed     Abstract available


    September 2022
  320. GREINER J, Goetz M, Schuler PJ, Bulach C, et al
    Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
    Br J Haematol. 2022;198:866-874.
    PubMed     Abstract available


  321. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    PubMed     Abstract available


  322. ALBERTSEN BK, Lynggaard LS, Schmiegelow K
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:e84-e85.
    PubMed    


  323. BRECCIA M, Olimpieri PP, Celant S, Olimpieri O, et al
    Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
    Br J Haematol. 2022;198:965-973.
    PubMed     Abstract available


  324. LI J, Liu L, Zhang R, Wan Y, et al
    Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
    Br J Haematol. 2022;198:1041-1050.
    PubMed     Abstract available


  325. VAN DER SLUIS IM, Bertrand Y, Baruchel A, Pieters R, et al
    Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:e82-e83.
    PubMed    


  326. MOGENSEN N, Saaranen E, Olsson E, Klug Albertsen B, et al
    Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.
    Br J Haematol. 2022;198:1032-1040.
    PubMed     Abstract available


  327. MOPPETT J
    Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:939-940.
    PubMed    


  328. TAYLOR GP, Cook LB
    A new paradigm for the management of ATL.
    Br J Haematol. 2022;198:941-942.
    PubMed    


  329. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    PubMed     Abstract available


  330. HARRINGTON P, Dillon R, Radia D, McLornan D, et al
    Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
    Br J Haematol. 2022;198:1011-1015.
    PubMed     Abstract available


  331. SONG Z, Tang G, Zhuang C, Wang Y, et al
    Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:994-1010.
    PubMed     Abstract available


    August 2022
  332. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    PubMed     Abstract available


  333. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    PubMed     Abstract available


  334. IMBERY JF, Heinzelbecker J, Jebsen JK, McGowan M, et al
    T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.
    Br J Haematol. 2022;198:556-573.
    PubMed     Abstract available


  335. WANG X, Tang G, Hu Z, Fang H, et al
    Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
    Br J Haematol. 2022;198:604-608.
    PubMed    


  336. SANCHEZ-VIZCAINO F, Tamayo C, Ramos F, Lainez-Gonzalez D, et al
    Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
    Br J Haematol. 2022;198:545-555.
    PubMed     Abstract available


  337. LU L, Kok CH, Dang P, Branford S, et al
    Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
    Br J Haematol. 2022;198:600-603.
    PubMed    


  338. PODVIN B, Guermouche H, Fournier E, Berthon C, et al
    Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region.
    Br J Haematol. 2022;198:413.
    PubMed    


  339. CHAN WY, Zhu C, Sanchez E, Gupta R, et al
    Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
    Br J Haematol. 2022;198:478-481.
    PubMed    


  340. HERAUDET L, Galtier J, Favre S, Peyraud F, et al
    VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
    Br J Haematol. 2022;198:523-527.
    PubMed     Abstract available


  341. JAMY O, Lin K, Worth S, Bachiashvili K, et al
    Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:e35-e37.
    PubMed    


  342. ALHAJ ISSA Z, Altwijri A, Alfayez M
    Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:414.
    PubMed    


  343. ADES L, Duployez N, Guerci-Bresler A, Laribi K, et al
    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
    Br J Haematol. 2022;198:535-544.
    PubMed     Abstract available


  344. RUSSELL NH, Hills RK, Kjeldsen L, Clark RE, et al
    A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    Br J Haematol. 2022;198:528-534.
    PubMed     Abstract available


  345. VALTIS YK, Place AE, Silverman LB, Vrooman LM, et al
    Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:421-430.
    PubMed     Abstract available


  346. VOLPE VO, Al Ali N, Chan O, Padron E, et al
    Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Br J Haematol. 2022;198:713-720.
    PubMed     Abstract available


  347. MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
    Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:790-793.
    PubMed    


  348. GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
    Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:780-784.
    PubMed    


  349. LAURA CS, Ana FM, Ines LH
    Pure erythroid leukaemia mimicking metastatic carcinoma.
    Br J Haematol. 2022;198:617.
    PubMed    


    July 2022
  350. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    PubMed     Abstract available


  351. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
    PubMed    


  352. MEYER LK, Delgado-Martin C, Sharp PP, Huang BJ, et al
    Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:137-141.
    PubMed     Abstract available


  353. GHANDILI S, Kluger MA, Leitner T, Grahammer F, et al
    Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation.
    Br J Haematol. 2022;198:199-202.
    PubMed    


  354. KRIEL M, Opie J, Louw V, Musekwa E, et al
    Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12.
    Br J Haematol. 2022;198:8.
    PubMed    


  355. PIMENTEL-VILLAR MA, Morales-Camacho RM, Vargas MT, Jimenez-Jambrina M, et al
    Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.
    Br J Haematol. 2022;198:7.
    PubMed    


  356. CLAXTON DF
    Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
    Br J Haematol. 2022;198:9-10.
    PubMed    


  357. SIDHU J, Masurekar AN, Gogoi MP, Fong C, et al
    Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
    Br J Haematol. 2022;198:142-150.
    PubMed     Abstract available


  358. WANG J, Jiang H, Jing Y, Su L, et al
    Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2022;198:e3-e8.
    PubMed    


  359. VOSO MT, Pandzic T, Falconi G, Dencic-Fekete M, et al
    Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
    Br J Haematol. 2022;198:103-113.
    PubMed     Abstract available


  360. DE PROPRIS MS, Musiu P, Intoppa S, Nardacci MG, et al
    Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
    Br J Haematol. 2022;198:e28-e31.
    PubMed    


  361. STENGEL S, Petrie KR, Sbirkov Y, Stanko C, et al
    Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Br J Haematol. 2022;198:338-348.
    PubMed     Abstract available


  362. DHUNPUTH C, Strullu M, Petit A, Merched M, et al
    Single-dose (4.5 mg/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
    Br J Haematol. 2022;198:373-381.
    PubMed     Abstract available


  363. SHIVAROV V, Grigorova D
    Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
    Br J Haematol. 2022;198:e23-e25.
    PubMed    


  364. GUO JJ, Cao L, Zhu HY, Miao Y, et al
    T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases.
    Br J Haematol. 2022;198:e18-e22.
    PubMed    


    June 2022
  365. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    PubMed    


  366. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    PubMed     Abstract available


  367. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.
    PubMed    


  368. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.
    PubMed    


  369. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.
    PubMed    


  370. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed     Abstract available


  371. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.
    PubMed    


  372. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed     Abstract available


  373. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed     Abstract available


  374. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed     Abstract available


  375. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed     Abstract available


    May 2022
  376. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available


  377. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available


  378. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    PubMed     Abstract available


  379. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.
    PubMed    


  380. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    PubMed     Abstract available


  381. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    PubMed     Abstract available


  382. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.
    PubMed    


  383. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    PubMed     Abstract available


  384. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    PubMed     Abstract available


  385. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.
    PubMed    


  386. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    PubMed     Abstract available


  387. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available


  388. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    PubMed     Abstract available


  389. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.
    PubMed    


    April 2022
  390. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.
    PubMed    


  391. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    PubMed     Abstract available


  392. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.
    PubMed    


  393. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    PubMed     Abstract available


  394. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    PubMed     Abstract available


  395. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.
    PubMed    


  396. BRANFORD S
    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.
    PubMed    


  397. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    PubMed     Abstract available


  398. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available


  399. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.
    PubMed    


  400. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available


  401. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.
    PubMed    


  402. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.
    PubMed    


    March 2022
  403. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    PubMed     Abstract available


  404. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    PubMed     Abstract available


  405. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    PubMed     Abstract available


  406. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    PubMed     Abstract available


  407. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.
    PubMed    


  408. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.
    PubMed    


  409. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    PubMed     Abstract available


  410. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.
    PubMed    


  411. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    PubMed     Abstract available


  412. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.
    PubMed    


  413. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    PubMed     Abstract available


  414. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.
    PubMed    


  415. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    PubMed     Abstract available


  416. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.
    PubMed    


  417. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    PubMed     Abstract available


    February 2022
  418. CLAUDIANI S
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.
    PubMed    


  419. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    PubMed     Abstract available


  420. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.
    PubMed    


  421. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    PubMed     Abstract available


  422. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    PubMed     Abstract available


  423. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    PubMed     Abstract available


  424. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    PubMed     Abstract available


  425. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.
    PubMed    


  426. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.
    PubMed    


  427. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.
    PubMed    


  428. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available


  429. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    PubMed     Abstract available


  430. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    PubMed     Abstract available


  431. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    PubMed     Abstract available


  432. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    PubMed     Abstract available


  433. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.
    PubMed    


  434. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    PubMed     Abstract available


  435. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.
    PubMed    


    January 2022
  436. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.
    PubMed    


  437. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.
    PubMed    


  438. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.
    PubMed    


  439. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    PubMed    


  440. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    PubMed    


  441. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.
    PubMed    


  442. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.
    PubMed    


  443. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    PubMed     Abstract available


  444. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    PubMed     Abstract available


  445. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.
    PubMed    


  446. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.
    PubMed    


  447. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    PubMed     Abstract available


  448. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.
    PubMed    


  449. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    PubMed     Abstract available


    December 2021
  450. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.
    PubMed    


  451. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    PubMed     Abstract available


  452. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    PubMed     Abstract available


  453. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    PubMed     Abstract available


  454. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    PubMed     Abstract available


    November 2021
  455. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    PubMed    


  456. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


  457. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    PubMed     Abstract available


  458. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.
    PubMed    


  459. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    PubMed    


  460. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.
    PubMed    


  461. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    PubMed     Abstract available


  462. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.
    PubMed    


  463. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    PubMed     Abstract available


    October 2021
  464. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available


  465. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.
    PubMed    


  466. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.
    PubMed    


  467. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.
    PubMed    


  468. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.
    PubMed    


  469. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    PubMed     Abstract available


  470. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available


  471. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    PubMed     Abstract available


  472. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.
    PubMed    


  473. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.
    PubMed    


    September 2021
  474. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    PubMed    


  475. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available


  476. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.
    PubMed    


  477. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available



  478. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    PubMed    


  479. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    PubMed     Abstract available


  480. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.
    PubMed    


  481. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.
    PubMed    


  482. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.
    PubMed    


    August 2021
  483. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  484. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available


  485. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.
    PubMed    


  486. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.
    PubMed    


  487. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


  488. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.
    PubMed    


  489. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    PubMed     Abstract available


  490. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    PubMed     Abstract available


  491. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    PubMed     Abstract available


  492. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.
    PubMed    


  493. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    PubMed     Abstract available


  494. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    PubMed    


  495. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.
    PubMed    


  496. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.
    PubMed    


    July 2021
  497. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available


  498. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available


  499. HEHLMANN R
    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.
    PubMed    


  500. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    PubMed     Abstract available


  501. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    PubMed     Abstract available


  502. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    PubMed     Abstract available


  503. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    PubMed     Abstract available


  504. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.
    PubMed    


  505. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    PubMed     Abstract available


  506. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    PubMed     Abstract available


  507. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    PubMed     Abstract available


  508. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    PubMed     Abstract available


  509. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.
    PubMed    


  510. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    PubMed     Abstract available


  511. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    PubMed     Abstract available


  512. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    PubMed     Abstract available


  513. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    PubMed     Abstract available


  514. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.
    PubMed    


  515. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available


  516. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    PubMed     Abstract available


  517. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    PubMed     Abstract available


  518. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    PubMed     Abstract available


  519. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    PubMed     Abstract available


  520. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    PubMed     Abstract available


  521. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.
    PubMed    


  522. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.
    PubMed    


    June 2021
  523. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
    PubMed    


  524. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available


  525. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available


  526. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available


  527. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available


  528. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  529. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.
    PubMed    


  530. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.
    PubMed    


  531. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.
    PubMed    


  532. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available


  533. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available


  534. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.
    PubMed    


  535. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available


  536. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available


  537. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available


  538. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available


    May 2021
  539. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.
    PubMed    


  540. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.
    PubMed    


  541. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available


  542. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available


  543. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available


  544. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available


  545. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available


  546. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.
    PubMed    


  547. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.
    PubMed    


  548. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available


  549. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available


  550. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available


    April 2021
  551. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  552. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.
    PubMed    


  553. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.
    PubMed    


  554. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available


  555. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.
    PubMed    


  556. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  557. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available


  558. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  559. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available


  560. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available


  561. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available


  562. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available


  563. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available


  564. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available


  565. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available


    March 2021
  566. HASSERJIAN RP
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.
    PubMed    


  567. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.
    PubMed    


  568. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available


  569. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.
    PubMed    


  570. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.
    PubMed    


  571. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available


  572. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available


  573. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available


  574. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.
    PubMed    


  575. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available


    February 2021
  576. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available


  577. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.
    PubMed    


  578. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.
    PubMed    


  579. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available


  580. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    PubMed    


  581. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    PubMed    


  582. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    PubMed    


  583. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available


  584. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available


  585. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available


  586. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available


    January 2021
  587. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.
    PubMed    


  588. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available


  589. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.
    PubMed    


  590. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available


  591. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.
    PubMed    


  592. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.
    PubMed    


  593. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available


  594. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.
    PubMed    


  595. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.
    PubMed    


  596. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available


  597. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available


  598. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available


  599. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available


  600. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available


    December 2020
  601. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    PubMed    


    November 2020
  602. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    PubMed    


  603. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available


    October 2020
  604. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    PubMed    


    April 2020
  605. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.